Poster Presentations

1. Willis M, Durkin M, Neslusan C, Traina S, Nilsson A. Estimated Renal and Cardiovascular Outcomes and Cost Offsets in Patients with Type 2 Diabetes (T2D) and Diabetic Nephropathy (DKD) Treated with Canagliflozin. Poster presentation at ISPOR 25th Annual International Meeting (Virtual meeting) 2020.

2. Liu A, Bech PG, Fridhammar A, Nilsson A, Willis M, Nuhoho S. Cost Effectiveness of Oral  Semaglutide 14 mg vs Empagliflozin 25 mg in Canada. Poster presentation at ADA 80th meeting. virtual meeting 2020.

3. Willis M, Neslusan C, Nilsson A, Asseburg C. Assessing the Value of Canagliflozin Versus Sitagliptin as Second-Line Therapy in the United States: The Importance of Considering Evidence from the CANVAS Program. Poster presentation at 78th ADA Orlando, USA 2018.

4. Nilsson A, Willis M, Neslusan C. A Review of the Costs of Lower-extremity Amputations in Patients with Diabetes in the United States. Poster presentation at ISPOR 23rd Annual International Meeting. Baltimore, MD, USA 2018.

5. Garcia-Sanchez J, Willis M, Nilsson A, Ericson O, Ball P. Estimated events avoided and cost offsets associated with using canagliflozin to treat T2DM patients with high risk of or established cardiovascular disease (CVD) in England. Poster presentation at ISPOR 21th European Annual Meeting. Barcelona, Spain 2018.

6. Willis M, Neslusan C, Johansen P, Nilsson A. The Importance of Considering the Evolving Evidence Base on Cardiovascular Effects of Anti-Hyperglycemic Agents on Estimates of ‘Value for Money’. Poster presentation at 77th ADA San Diego, USA 2017.

7. Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, et al. Time Until Insulin Initiation for Canagliflozin Versus Dapagliflozin and Empagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus in the UK. Poster presentation at ISPOR 21st Annual International Meeting. Washington DC, USA 2016.

8. Schroeder M, Chan E, Willis M, Johansen P, Nilsson A, Schubert A, et al. Time Until Insulin Initiation for Canagliflozin Versus Sitagliptin in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus in the UK. Poster presentation at ADA 76th Scientific Sessions. New Orleans, LA, USA 2016.

9. Neslusan C, Willis M, Johansen P, Schroeder M, Nilsson A, Chan E, et al. The Role of Estimated Glomerular Filtration Rate in Cost-Effectiveness Analyses Using Canagliflozin vs Sulfonylurea to Treat Type 2 Diabetes Mellitus. Poster presentation at ADA 76th Scientific Sessions. New Orleans, LA, USA 2016.

10. Asseburg C, Willis M, Johansen P, Nilsson A, Neslusan C, Schroeder M. Update of the Model Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Poster Presentation at ISPOR 21st Annual International Meeting. Washington DC, USA 2016.

11. Willis M, Neslusan C, Martin S, Johansen P, Asseburg C, O’Brien D. Threshold-Based Metrics may not Value all Benefits of Improved HbA1c: Implications for Health Care Resource Allocation. Poster presentation at International Diabetes Federation – World Diabetes Congress. Vancouver, Canada 2015.

12. Willis M, Johansen P, Neslusan C. The Effect of Treatment Intensification Assumptions on Estimates of Cost-Effectiveness in Type 2 Diabetes Mellitus. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.

13. Teschemaker A, Neslusan C, Sabapathy S, Yoong K, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin Versus Saxagliptin Among Older Individuals Living with Type 2 Diabetes Mellitus in Canadas. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.

14. Schroeder M, Johansen P, Willis M, Neslusan C. The Cost-Effectiveness of Canagliflozin Versus Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes Mellitus as Monotherapy in the United Kingdom. Poster presentation at ISPOR 18th European Annual Meeting. Milan, Italy 2015.

15. Schroeder M, Johansen P, Willis M, Neslusan C. The Cost-Effectiveness of Canagliflozin Versus Sulphonylurea in Patients with Type 2 Diabetes With inadequate Control on Metformin Monotherapy in the United Kingdom. Poster presentation at Diabetes UK Professional Conference, London, U.K 2015.

16. Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. Impact of Weight-related Utilities on the Cost-Effectiveness of Canagliflozin Versus Sitagliptin as Third-line Therapy in Type 2 Diabetes Mellitus in a Canadian Setting. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.

17. Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea in a Canadian Setting. Poster presentation at ISPOR 20th Annual Meeting Philadelphia, Pennsylvania, USA 2015.

18. Pititto L, Neslusan C, Teschemaker A, Johansen P, Willis M, Asano E, et al. Cost-effectiveness of Canagliflozin Versus Sitagliptin as Add-on to Metformin Plus Sulfonylurea in Patients with Type 2 Diabetes Mellitus in Brazil. Poster presentation at ISPOR 5th Latin America Conference Santiago, Chile 2015.

19. Bacon T, Willis M, Johansen P, Neslusan C. Time Until Insulin Initiation for Canagliflozin Versus Dapagliflozin in Dual and Triple Therapy for Type 2 Diabetes Mellitus in Ireland. Poster presentation at ISPOR 20th Annual Meeting. Philadelphia, Pennsylvania, USA 2015.

20. Yoong K, Willis M, Johansen P, Yim C, Teschemaker A, Neslusan C. The Impact of Alternative Estimates of Disutilities Associated with Hypoglycemia on Net QALYs: Canagliflozin versus Sitagliptin as Add-On Therapy in Individuals with Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled on a Background of Metformin (MET) plus Sulfonylurea (SU) in the Canadian Setting. Poster presentation at ISPOR 19th Annual International Meeting. Montreal, QC, Canada 2014.

21. Thompson G, Schroeder M, Neslusan C, Willis M, Johansen P, Teschemaker A. The Cost-Effectiveness of Canagliflozin (CANA) versus Sitagliptin (SITA) as Third-Line Therapy in the Treatment of Type 2 Diabetes Mellitus in the U.K. Poster presentation at EASD 50th Annual Meeting. Stockholm, Sweden 2014.

22. Schroeder M, Johansen P, Thompson G, Neslusan C, Willis M. The Cost-Effectiveness of Canagliflozin Versus Dapagliflozin in Patients with Type 2 Diabetes Mellitus with Inadequate Control on metformin Monotherapy in the United Kingdom. Poster presentation at ISPOR 17th Annual European Congress Amsterdam, Netherlands 2014.

23. Neslusan C, Teschemaker A, Martin S, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin (CANA) Versus Dapagliflozin (DAPA) as an Add-On to Metformin (MET) in Patients with Type 2 Diabetes Mellitus (T2DM) in the United States. Poster presentation at ISPOR 19th Annual International Meeting. Montreal, QC, Canada 2014.

24. Neslusan C, Martin S, Teschemaker A, Vo L, Johansen P, Willis M. Cost-effectiveness Analysis of Canagliflozin Versus Maximally Titrated Glimepiride as an Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in the United States. Poster presentation at ADA 74th Scientific Sessions. San Francisco, CA, USA 2014.

25. Martin S, Neslusan C, Vo L, Teschemaker A, Johansen P, Willis M. The Cost-Effectiveness of Canagliflozin (CANA) Versus Sitagliptin (SITA) as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US. Poster presentation at ADA 74th Scientific Sessions. San Francisco, CA, USA 2014.

26. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. The Cost-Effectiveness of Canagliflozin Versus Liraglutide in Patients with Type 2 Diabetes Failing to Achieve Glycaemic Control on Metformin Monotherapy in Ireland. Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands 2014.

27. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. The Cost-Effectiveness of Canagliflozin Versus Insulin Secretagogues (Sulphonylureas) or Insulin in Patients with Type 2 Diabetes Mellitus as Add-on to Metformin in Ireland. Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands 2014.

28. Bacon T, Willis M, Johansen P, Neslusan C, Nuhoho S, Worbes-Cerezo M. Is Canagliflozin Cost-Effective Compared to Sitagliptin Across Multiple Lines of type 2 Diabetes Mellitus Therapy in Ireland? Poster presentation at ISPOR 17th Annual European Congress. Amsterdam, Netherlands2014.

29. Willis M, Johansen P, Schroeder M, Thompson G, Girod I, Neslusan C. Sources of Long-term Quality Adjusted Life (QALY) Gains for Canagliflozin (CANA) versus Sitagliptin (SITA) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.

30. Thompson G, Willis M, Johansen P, Neslusan C, Schroeder M, Girod I. Assessment of the Key Drivers of the Cost-Effectiveness in the Economic Modelling of Canagliflozin (CANA) versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress, Dublin, Ireland 2013.

31. Schroeder M, Willis M, Johansen P, Girod I, Neslusan C, Thompson G. Impact of Weight Trajectory on Cost-Effectiveness of Treatments of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.

32. Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia A, Puig A. A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Dual Therapy in Mexico. Poster presentation at ISPOR 4th Latin America Conference. Buenos Aires, Argentina 2013.

33. Neslusan C, Johansen P, Willis M, Martin S. A Health Economic Analysis of the Long-term Benefits and Associated Cost Offsets of Canagliflozin Monotherapy in the United States. Poster presentation at ADA 73rd Scientific Sessions. Chicago, IL, USA 2013.

34. Girod I, Willis M, Johansen P, Schroeder M, Thompson G, Neslusan C. Sources of Long-term Quality Adjusted Life (QALY) Gains for Canagliflozin (CANA) versus Glimepiride (GLIM) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the UK Setting. Poster presentation at ISPOR 16th Annual European Congress. Dublin, Ireland 2013.

35. Willis M, He J, Neslusan C, Johansen P, Worbes-Cerezo M. The Importance of HbA1c Evolution in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 15th Annual European Congress. Berlin, Germany 2012.

36. Teschemaker A, Johansen P, Brazier N, Neslusan C, Willis M. The Health Impact of Getting to Glucose, Systolic Blood Pressure (SBP), and Serum Cholesterol Goals in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada. Poster presentation at CDA/CSEM Professional Conference and Annual Meetings. Vancouver, Canada 2012.

37. Johansen P, Teschemaker A, Brazier N, Neslusan C, Willis M. Effect of Modest Weight Loss on Long-term Health Outcomes in People Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada. Poster presentation at CDA/CSEM Professional Conference and Annual Meetings. Vancouver, Canada 2012.

38. Willis M, Neslusan C, He J, Worbes-Cerezo M. The Economic Impact of Weight Loss in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger than 50 in Sweden. Poster presentation at ISPOR 14th Annual European Congress. Madrid, Spain 2011.

39. He J, Neslusan C, Willis M, Worbes-Cerezo M. The Cost-Effectiveness of getting to Glucose, Blood Pressure, and Lipid Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) and Younger Than Fifty in Sweden. Poster presentation at ISPOR 14th Annual European Congress. Madrid, Spain 2011.

40. Willis M, He J, Neslusan C, Chievic E. The Economic Importance of Metabolic Memory in the Treatment of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 13th Annual European Congress. Prague, Czech Republic 2010.

41. Willis M, Asseburg C, Neslusan C, He J, Ingham M. The Economic Impact of Weight Loss for Patients with Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) in the US. Poster presentation at ISPOR 15th Annual Meeting. Atlanta, GA, USA 2010.

42. He J, Willis M, Asseburg C, Neslusan C, Persson U. Simulation of the Chinese Diabetes Treatment Guideline using the IHE/JNJ Diabetes Cost-Effectiveness Model. Poster presentation at World Congress on Health Economics, iHEA. Beijing, China 2009.

43. Asseburg C, Willis M, Persson U, Neslusan C, He J. Validation of the IHE/JJPS Economic Simulation Model of Type 2 Diabetes Mellitus (T2DM). Poster presentation at ISPOR 14th Annual Meeting Orlando, Florida, USA 2009.

44. Willis M, Borg S, Persson U, Neslusan C. Cost-Effectiveness of Sulfonylureas versus Metformin as First-Line Therapy in Newly Diagnosed Type 2 Diabetes. Poster presentation at ADA 67th Scientific Sessions. Chicago, Illinois, USA 2007.

45. Willis M, Asseburg C, Borg S, Persson U, Neslusan C. Cost-Effectiveness of Strict “Get To Goal” Treatment Directives in the Treatment of Younger Patients with Newly Diagnosed Type 2 Diabetes Mellitus. Poster presentation at ISPOR 9th Annual European Congress. Dublin, Ireland 2007.

Contact


For more information, please contact: diabetesmodelling@ihe.se